Biotech Makes a Comeback

 | May 10, 2013 | 12:52 PM EDT  | Comments
  • Comment
  • Print Print
  • Print
Stock quotes in this article:

biib

,

celg

,

regn

,

alxn

,

gild

So, Celgene (CELG), Regeneron (REGN), Biogen Idec (BIIB) and Alexion (ALXN) rested, recharged and now are returning to their winning ways. Only Gilead (GILD) has yet to turn to the black, which means it's probably time to buy that one, too.

These stocks had the classic kind of recharge that you want to see if you are a bull. They must be as annoying as all get out if you are a bear because all that seems to happen with them is that people pay more for the same news over and over in classic multiple-expansion theory. That's always regarded as a total red flag by the purists, but has worked just fine for ages now, so it has made all of these a tough short.

Take Regeneron, one of my absolute favorites with the best macular degeneration drug. The company reported spectacular results and then rallied, although the results were spectacular if you actually just came to believe that Regeneron isn't that good. It sure is.

Then it got added to the S&P, which caused a short spike. The usual arbitrageurs then shorted the stock, betting post admission it would give up the ghost.

But virtually at the same moment that it was added, Allergan announced, in a true shocker, that its competitive drug to Regeneron wasn't up to snuff -- yet --and that caused the next spike up. Then the market rotated to the materials stocks, which are giving up the ghost today, and the move is now back in full swing based on, well, a rotation back into these stocks as the market takes note of the pipelines and the scrips that remain strong.

That means you can go back to Biogen, which people are doing right now as the MS scrips are real good. And I suspect they will go back to Gilead, too, as there's tons of drugs in the pipeline there, too.

Just a natural change in leadership from specs and materials back to what brought us up here in the first place.

Columnist Conversations

The powerful rally in CME continues. The stock is up over 2.5% today and is working on its sixth straigh...
The second weekly support zone held in this one. The first meaningful resistance I see on the way up is the 1...
Can the U.S. balance its trade deficit by exporting bad ideas? Xinhua is carrying a story about China possibl...
Stocks to watch this morning include… Rite Aid has it wrong today with an earnings warning lowering out...

BEST IDEAS

REAL MONEY'S BEST IDEAS

Columnist Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.